Precision BioSciences, Inc. (NASDAQ:DTIL) CEO Sells $172,033.46 in Stock

Precision BioSciences, Inc. (NASDAQ:DTIL) CEO Michael Amoroso sold 36,838 shares of the firm’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $4.67, for a total value of $172,033.46. Following the completion of the sale, the chief executive officer now owns 107,087 shares in the company, valued at approximately $500,096.29. This represents a 25.60 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Michael Amoroso also recently made the following trade(s):

• On Monday, November 4th, Michael Amoroso sold 3,012 shares of Precision BioSciences stock. The shares were sold at an average price of $8.19, for a total value of $24,668.28.

Precision BioSciences Stock Performance

Shares of NASDAQ DTIL traded up $0.41 during trading hours on Wednesday, reaching $4.97. The stock had a trading volume of 269,389 shares, compared to its average volume of 1,803,615. The firm has a 50-day moving average of $5.62 and a 200-day moving average of $8.04. The firm has a market cap of $38.12 million, a price-to-earnings ratio of 82.85 and a beta of 1.51. The company has a current ratio of 9.22, a quick ratio of 9.22 and a debt-to-equity ratio of 0.34. Precision BioSciences, Inc. has a fifty-two week low of $3.61 and a fifty-two week high of $19.43.

Institutional Investors Weigh In On Precision BioSciences

A hedge fund recently raised its stake in Precision BioSciences stock. Janus Henderson Group PLC lifted its holdings in shares of Precision BioSciences, Inc. (NASDAQ:DTIL) by 10.9% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 702,069 shares of the company’s stock after buying an additional 68,943 shares during the period. Janus Henderson Group PLC owned approximately 9.15% of Precision BioSciences worth $6,322,000 at the end of the most recent quarter. Institutional investors and hedge funds own 37.99% of the company’s stock.

Analysts Set New Price Targets

DTIL has been the subject of a number of research analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 price target on shares of Precision BioSciences in a report on Friday, January 10th. BMO Capital Markets upgraded shares of Precision BioSciences from a “market perform” rating to an “outperform” rating and set a $34.00 target price for the company in a report on Friday, January 10th.

About Precision BioSciences

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.